Biomarkers in Heart Failure

Slides:

Advertisements

Similar presentations

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Advertisements

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

Heart Failure: From Failure to Success

A view of Novel Cardiac Biomarkers in Heart Failure.

Natural History of Heart Failure

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Path to an Angiotensin Receptor Antagonist-Neprilysin.

NTproBNP for the Exclusion of Heart Failure Richard Blakey.

The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.

R2 김재민 / Prof. 박명재 Journal conference 1.

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

Biomarkers that “guide” therapy

DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study M. Lazo, Y. Chen, J.W. McEvoy, C. Ndumele, S. Konety,

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Stephen W. Waldo et al. JACC 2008;51:

Heart Failure and Hospital Readmissions

A CASE CHALLENGE IN HFrEF:

Cardiac Biomarkers.

Select Topics in Cardiovascular Medicine

Cost Effectiveness and Optimal Outcomes in HF

Clyde W. Yancy et al. JACC 2017;70:

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Cardiovascular Comorbidities A Common Occurrence With COPD

Selected Highlights of the Latest Advances in PAH

Preventing Heart Failure Readmission and Progression

Antithrombotic Protection in CAD and HF

Biomarker-Guided HF Therapy: Is It Cost-Effective?

Managing Depression is a Team Effort:

Expert Insights on Complex Clinical Cases of Edema

The Heart Failure Team Heart Failure Care Map First 24 hours.

Evaluating New Therapies in HF

Orly Vardeny et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Multidisciplinary Management of Hyperkalemia:

Overcoming Clinical Inertia

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

New Strategies to Reduce HF Readmissions

Pharmacotherapy for Diabetic Coronary Disease:

Nicholas Wettersten, MD, Alan S. Maisel, MD

Program Goals Background: Anticoagulation in Patients With VTE.

Role of N-terminal pro B-type natriuretic peptide in identifying patients at high risk for adverse outcome after emergent non-cardiac surgery S. Farzi,

Improving Adherence to Antiplatelet Therapy After an ACS Event

Perspective on the Multidisciplinary Management of PAH

Baseline Characteristics by Baseline N-BNP Level

Contemporary Considerations in Biomarker-Guided Therapy

The Research Question Heart failure (HF) and atrial fibrillation (AF) frequently coexist and are associated with many adverse outcomes HF and AF share.

HF-Related Hospitalization and Readmissions

PAH Pathways: What Do the Data Tell Us?”

Algorithm for the outpatient management of pulmonary embolism (PE)

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

Pulmonary Arterial Hypertension and Hospitalizations

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

My PAH Patient.

Top Tips in Evidence-Based Care for HFrEF

Associations of peripartum biomarker levels with e' at 1 month postpartum (PP2). Associations of peripartum biomarker levels with e' at 1 month postpartum.

Key Data on Improving Outcomes in HF Patients

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Spearman’s rank correlation between preoperative serum levels of BNP/NT-proBNP and expression of HIF-2 alpha and preoperative serum level of VEGF. There.

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

Overall survival in all cases.

Standardised regression coefficients between blood variable levels and echocardiographic measurements. Standardised regression coefficients between blood.

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Biomarkers in Heart Failure

Learning Objectives

BNP Reflects Ventricular Wall Stress

LaPlace’s Law

Vulnerabilities of Natriuretic Peptides

Limitation of Natriuretic Peptides at Presentation for Early Prognosis Results of the BACH study

Natriuretic Peptide Treatment Response Absolute Target and Percent Change

Prognosis Summary for Natriuretic Peptides Based on Timing of Measurement During Index Hospitalization for Acute HF

Additive Value of ST2 to NT-proBNP in Long-term Prognosis

Therapies With Effects on B-Type Natriuretic Peptide Levels

PROTECT Primary End Point

Guided Therapy Combined Analyses: Mortality

Mechanism of Action of LCZ696

Neprilysin Inhibition A New Paradigm for HF Care?

LCZ696 and Biomarkers

NT-proBNP Predicts Cardiovascular Outcomes in Asymptomatic Community Dwelling Older Adults The Cardiovascular Health study (n = 4312)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)